Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Total Liabilities (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Total Liabilities readings, the most recent being $57.3 million for Q1 2026.

  • On a quarterly basis, Total Liabilities fell 51.06% to $57.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $57.3 million, a 51.06% decrease, with the full-year FY2025 number at $58.7 million, down 71.54% from a year prior.
  • Total Liabilities hit $57.3 million in Q1 2026 for Atara Biotherapeutics, down from $58.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $264.7 million in Q4 2023 to a low of $57.3 million in Q1 2026.
  • Median Total Liabilities over the past 5 years was $206.4 million (2024), compared with a mean of $180.4 million.
  • Biggest five-year swings in Total Liabilities: surged 37.09% in 2023 and later crashed 71.54% in 2025.
  • Atara Biotherapeutics' Total Liabilities stood at $249.8 million in 2022, then grew by 5.99% to $264.7 million in 2023, then decreased by 22.04% to $206.4 million in 2024, then crashed by 71.54% to $58.7 million in 2025, then dropped by 2.43% to $57.3 million in 2026.
  • The last three reported values for Total Liabilities were $57.3 million (Q1 2026), $58.7 million (Q4 2025), and $66.8 million (Q3 2025) per Business Quant data.